Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy

Nature Communications

Volumn 7, Issue , 2016, Pages

  Findlay, John M ^a,b   Castro Giner, Francesc ^a   Makino, Seiko ^a   Rayner, Emily ^a   Kartsonaki, Christiana ^c   Cross, William ^d   Kovac, Michal ^a   Ulahannan, Danny ^a   Palles, Claire ^a   Gillies, Richard S ^b   Macgregor, Thomas P ^b   Church, David ^a   Maynard, Nicholas D ^b   Buffa, Francesca ^c   Cazier, Jean Baptiste ^e   Graham, Trevor A ^d   Wang, Lai Mun ^f,g   Sharma, Ricky A ^c,g   Middleton, Mark ^c,g   Tomlinson, Ian ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^g NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; FLUOROURACIL; OXALIPLATIN; PROTEIN; PROTEIN CCND2; PROTEIN P53; PROTEIN PIK3CA; PROTEIN SF3B1; PROTEIN TAF1; SMAD4 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CCND2 PROTEIN, HUMAN; CYCLIN D2; DNA; HISTONE ACETYLTRANSFERASE; PHOSPHOPROTEIN; RNA SPLICING FACTOR; SF3B1 PROTEIN, HUMAN; SMALL NUCLEAR RIBONUCLEOPROTEIN; TATA BINDING PROTEIN ASSOCIATED FACTOR; TATA-BINDING PROTEIN ASSOCIATED FACTOR 250 KDA; TRANSCRIPTION FACTOR IID; TUMOR PROTEIN;

CANCER; CHEMOTHERAPY; DISEASE TREATMENT; GENETIC ANALYSIS; GENOME; HETEROGENEITY; MUTATION; POPULATION BOTTLENECK;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLONAL EVOLUTION; COLORECTAL CANCER; ESOPHAGEAL ADENOCARCINOMA; FEMALE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; HUMAN; INDEL MUTATION; MALE; MIDDLE AGED; MISSENSE MUTATION; MULTIPLE CYCLE TREATMENT; RECURRENCE FREE SURVIVAL; TREATMENT RESPONSE; ADENOCARCINOMA; COPY NUMBER VARIATION; DNA SEQUENCE; DRUG EFFECTS; ESOPHAGEAL NEOPLASMS; EXOME; GENE EXPRESSION REGULATION; GENETIC HETEROGENEITY; GENETICS; METABOLISM; MUTATION; NEOADJUVANT THERAPY; PATHOLOGY; TUMOR RECURRENCE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; CLONAL EVOLUTION; CYCLIN D2; DNA COPY NUMBER VARIATIONS; DNA, NEOPLASM; ESOPHAGEAL NEOPLASMS; EXOME; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC HETEROGENEITY; HISTONE ACETYLTRANSFERASES; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOADJUVANT THERAPY; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PHOSPHOPROTEINS; RIBONUCLEOPROTEIN, U2 SMALL NUCLEAR; RNA SPLICING FACTORS; SEQUENCE ANALYSIS, DNA; TATA-BINDING PROTEIN ASSOCIATED FACTORS; TRANSCRIPTION FACTOR TFIID;

EID: 84962654180     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms11111     Document Type: Article

References (64)

1. Mandard, A. M. et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 73, 2680-2686 (1994).
2. Davies, A. R. et al. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction. J. Clin. Oncol. 32, 2983-2990 (2014).
3. Kreso, A. et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science (New York, NY) 339, 543-548 (2013).
4. Benvenuti, S. et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 67, 2643-2648 (2007).
5. Gifford, G., Paul, J., Vasey, P. A., Kaye, S. B. & Brown, R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin. Cancer Res. 10, 4420-4426 (2004).
6. Harris, A. L. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer 2, 38-47 (2002).
7. Beck, B. & Blanpain, C. Unravelling cancer stem cell potential. Nat. Rev. Cancer 13, 727-738 (2013).
8. Junttila, M. R. de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501, 346-354 (2013).
9. Klemm, F. & Joyce, J. A. Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol. 25, 198-213 (2015).
10. Bachas, C. et al. The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse. Leukemia 26, 1313-1320 (2012).
11. Bachas, C. et al. High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine. Blood 116, 2752-2758 (2010).
12. Parkin, B. et al. Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia. Blood 121, 369-377 (2013).
13. Ding, L. et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481, 506-510 (2012).
14. Schuh, A. et al. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood 120, 4191-4196 (2012).
15. Landau, D. A. et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152, 714-726 (2013).
16. Walter, M. J. et al. Clonal architecture of secondary acute myeloid leukemia. N. Engl. J. Med. 366, 1090-1098 (2012).
17. Okosun, J. et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat. Genet. 46, 176-181 (2014).
18. de Bruin, E. C. et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science (New York, NY) 346, 251-256 (2014).
19. Gerlinger, M. et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46, 225-233 (2014).
20. Zhang, J. et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science (New York, NY) 346, 256-259 (2014).
21. Gerlinger, M. & Swanton, C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br. J. Cancer 103, 1139-1143 (2010).
22. Diaz, Jr L. A. et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537-540 (2012).
23. Ellis, M. J. et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486, 353-360 (2012).
24. Wagle, N. et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29, 3085-3096 (2011).
25. Turke, A. B. et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17, 77-88 (2010).
26. Corcoran, R. B. et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2, 227-235 (2012).
27. Lord, C. J. & Ashworth, A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat. Med. 19, 1381-1388 (2013).
28. Jiang, Y. Z., Yu, K. D., Bao, J., Peng, W. T. & Shao, Z. M. Favorable prognostic impact in loss of TP53 and PIK3CA mutations after neoadjuvant chemotherapy in breast cancer. Cancer Res. 74, 3399-3407 (2014).
29. Klco, J. M. et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell 25, 379-392 (2014).
30. Meric-Bernstam, F. et al. Concordance of genomic alterations between primary and recurrent breast cancer. Mol. Cancer Ther. 13, 1382-1389 (2014).
31. Almendro, V. et al. Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Rep. 6, 514-527 (2014).
32. Johnson, B. E. et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science (New York, NY) 343, 189-193 (2014).
33. Kim, H. et al. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res. 25, 316-327 (2015).
34. Murugaesu, N. et al. Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy. Cancer Discov. 5, 821-831 (2015).
35. Patch, A. M. et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 521, 489-494 (2015).
36. Davies, A. R. et al. Factors associated with early recurrence and death after esophagectomy for cancer. J. Surg. Oncol. 109, 459-464 (2014).
37. Dulak, A. M. et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat. Genet. 45, 478-486 (2013).
38. Weaver, J. M. et al. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat. Genet. 46, 837-843 (2014).
39. Solomon, D. A. et al. Frequent truncating mutations of STAG2 in bladder cancer. Nat. Genet. 45, 1428-1430 (2013).
40. Gundem, G. et al. IntOGen: integration and data mining of multidimensional oncogenomic data. Nat. Methods 7, 92-93 (2010).
41. Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013).
42. Ross-Innes, C. S. et al. Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma. Nat. Genet. 47, 1038-1046 (2015).
43. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
44. Agrawal, N. et al. Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov. 2, 899-905 (2012).
45. Dulak, A. M. et al. Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res. 72, 4383-4393 (2012).
46. Nones, K. et al. Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. Nat. Commun. 5, 5224 (2014).
47. Sinicrope, F. A. & Sargent, D. J. Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin. Cancer Res. 18, 1506-1512 (2012).
48. Maley, C. C. et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat. Genet. 38, 468-473 (2006).
49. Blagosklonny, M. V. p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect. FASEBJ. 14, 1901-1907 (2000).
50. Griffith, M. et al. Optimizing cancer genome sequencing and analysis. Cell Syst. 1, 220-223 (2015).
51. Findlay, J., Middleton, M. & Tomlinson, I. A systematic review and metaanalysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage. Ann Oncol. 26, 624-644 (2014).
52. Lordick, F. et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 8, 797-805 (2007).
53. Lunter, G. & Goodson, M. Stampy: a statistical algorithm for sensitive and fast mapping of Illumina sequence reads. Genome Res. 21, 936-939 (2011).
54. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
55. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297-1303 (2010).
56. Rimmer, A. et al. Integrating mapping-, assembly-and haplotype-based approaches for calling variants in clinical sequencing applications. Nat. Genet. 46, 912-918 (2014).
57. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213-219 (2013).
58. Cingolani, P. et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly. (Austin). 6, 80-92 (2012).
59. Danecek, P. et al. The variant call format and VCFtools. Bioinformatics 27, 2156-2158 (2011).
60. Brunet, J. P., Tamayo, P., Golub, T. R. & Mesirov, J. P. Metagenes and molecular pattern discovery using matrix factorization. Proc. Natl Acad. Sci. USA 101, 4164-4169 (2004).
61. Roth, A. et al. PyClone: statistical inference of clonal population structure in cancer. Nat. Methods 11, 396-398 (2014).
62. Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568-576 (2012).
63. Nilsen, G. et al. Copynumber: efficient algorithms for single-and multi-track copy number segmentation. BMC Genomics 13, 591 (2012).
64. Niu, B. et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics 30, 1015-1016 (2014).